Sept. 5–6, 2019 • Houston, Texas
In the wake of the 2017 U.S. Food and Drug Administration approvals for Chimeric Antigen Receptor (CAR) T cell therapies for the treatment of patients with lymphoma and leukemia, adoptive cellular therapies have rapidly become a focal point for stakeholders across the field of cancer immunotherapy.
As this treatment modality has displayed unprecedented patient response and offers significant curative potential for cancer patients across the globe, SITC was proud to host an Adoptive Cellular Therapies Workshop to support both continued momentum and clinical advancement.
This two-day workshop brought together cancer immunotherapy experts to discuss and address challenges concerning the use and development of adoptive cellular therapies for the treatment of cancer patients.
Throughout seven didactic sessions and participation in collaborative working groups, attendees discussed a number of topics, including:
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
CIR WORKSHOP SCHEDULE
ACT WORKSHOP SCHEDULE
Enduring materials are now available. Click on the schedule above for the Cancer Immune Responsiveness Workshop or the Adoptive Cellular Therapies Workshop to access available enduring materials.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com